title: An economic analysis of premarriage prevention of hepatitis B transmission in Iran.
abstract: BACKGROUND
  To assess the economic aspects of HBV (hepatitis B virus) transmission prevention for premarriage individuals in a country with cultural backgrounds like Iran and intermediate endemicity of HBV infection.
  
  
  METHODS
  A cost-effectiveness analysis model was used from the health care system and society perspectives. The effectiveness was defined as the number of chronic HBV infections averted owing to one of the following strategies:1) HBsAg screening to find those would-be couples one of whom is HBsAg positive and putting seronegative subjects on a protection protocol comprising HBV vaccination, single dose HBIG and condom protection.2) HBsAg screening as above, in addition to performing HBcAb screening in the HBsAg negative spouses of the HBsAg positive persons and giving the protocol only to HBcAb negative ones.Sensitivity and threshold analyses were conducted.
  
  
  RESULTS
  The cost of each chronic infection averted was 202$ and 197$ for the strategies 1 and 2, respectively. Sensitivity analysis showed that strategy 2 was always slightly cheaper than strategy 1. The discounted threshold value for the lifetime costs of chronic liver disease, above which the model was cost saving was 2818$ in strategy 1 and 2747$ in strategy 2.
  
  
  CONCLUSIONS
  Though premarriage prevention of HBV transmission in the countries with cultural backgrounds similar to Iran seems cost saving, further studies determining precise costs of HBV infection in Iran can lead to a better analysis.
authors.affiliation: Research Center for Gastroenterology and Liver Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Iran. payad2000@yahoo.com
authors.forename: Peyman
authors.initials: P
authors.lastname: Adibi
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Rezailashkajani
authors.forename: Delnaz
authors.initials: D
authors.lastname: Roshandel
authors.forename: Negar
authors.initials: N
authors.lastname: Behrouz
authors.forename: Shahin
authors.initials: S
authors.lastname: Ansari
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Somi
authors.forename: Saeed
authors.initials: S
authors.lastname: Shahraz
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Zali
mesh_terms: D017280:Condoms / Q000191:economics; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000191:economics; D006801:Humans; D007136:Immunoglobulins / Q000191:economics; D007492:Iran / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D011291:Premarital Examinations / Q000191:economics* / Q000379:methods; D015995:Prevalence; D012680:Sensitivity and Specificity
chemical_list: D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin